MOA

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, March 7, 2024
Neoplasm, Research, Toxicity, SCCA, FOLFIRINOX, Trifluridine/tipiracil, PR, Society, Breast, Health, Poster, Immunotherapy, Anal cancer, Pancreatic cancer, Fast Track, Anal, Progression-free survival, SITC, Pelareorep, Annual general meeting, Congress, Cancer, Gastrointestinal cancer, AB, International, Cohort, ESMO, Conference, Safety, TILS, Tumor microenvironment, Clinical trial, Survival, MOA, Oncology, Colorectal cancer, TIL, Blood, FDA, TSX, Thought, Pancreatic Cancer Action Network, Anal canal, PDAC, Patient, ONC, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 were $4.2 million, compared to $3.7 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $4.7 million, compared to $4.8 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $8.6 million for the fourth quarter of 2022.

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights

Retrieved on: 
Friday, February 16, 2024
Caregiver, Education, Physician, Neurology, Biomarker, DMTS, Patient, Practitioner, MOA, Disease, Diagnosis, Moa, Tremor, Research, Pharmaceutical industry

Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.

Key Points: 
  • Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.
  • Further, critical to the success of future gene therapies and DMTs is the identification of biomarkers associated with PD.
  • This underscores the importance of manufacturers engaging with healthcare professionals to provide insights into emerging therapies and MOAs.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024
Scar, Brock University, Myotonic dystrophy, AMO, Zebrafish, WNT, Hamilton Health Sciences, SCD, Duchenne muscular dystrophy, Tideglusib, Facial muscles, McMaster University, Risk, Health, ICD, Phenotype, DSM-IV codes, Patient, Arrhythmogenic cardiomyopathy, Target, MOA, Hiro, ACM, Research, Pharmaceutical industry

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

Retrieved on: 
Thursday, February 15, 2024
Scar, Brock University, Myotonic dystrophy, AMO, Zebrafish, WNT, Hamilton Health Sciences, SCD, Duchenne muscular dystrophy, Tideglusib, Facial muscles, McMaster University, Risk, Health, ICD, Phenotype, DSM-IV codes, Patient, Arrhythmogenic cardiomyopathy, Target, MOA, Hiro, ACM, Research, Pharmaceutical industry

Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.

Key Points: 
  • Enrollment is set to begin in mid-2024 at 20 sites across Canada and will include a total of 120 participants who will be randomized in a 1:1 ratio.
  • The TaRGET trial is a critical first step in evaluating this potential."
  • This scarring increases the risk of dangerously fast heart rhythms that can lead to sudden cardiac death (SCD).
  • An implantable cardioverter defibrillator (ICD) is recommended for prevention of SCD for ACM patients considered at high risk for SCD.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

VISIBLE ALPHA LAUNCHES NEW BIOPHARMA PLATFORM

Retrieved on: 
Tuesday, February 6, 2024
Growth, Research, Clinical trial, News, Metadata, FDA, MOA, Alpha, Data and information visualization, Pharmaceutical industry

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Visible Alpha, a financial technology company that enhances the investment research process by extracting value from sell-side analyst models, research reports and corporate access events, today announced the launch of its newest data and granular financial information platform Visible Alpha BioPharma.  

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Visible Alpha, a financial technology company that enhances the investment research process by extracting value from sell-side analyst models, research reports and corporate access events, today announced the launch of its newest data and granular financial information platform Visible Alpha BioPharma.
  • With the launch of Visible Alpha BioPharma, Visible Alpha is providing investment professionals and drug developers with a one-stop-shop for comprehensive drug data and granular financial information to swiftly identify new opportunities, evaluate market competitiveness, gauge market expectations, analyze historical data, access forward-looking estimates and conduct rapid analysis at the drug level.
  • Visible Alpha's new BioPharma platform will allow investment, equity research, and drug development professionals to:
    Gain insights into market trends, investor sentiment and the changing projections surrounding drug performance with detailed financial data.
  • The new Visible Alpha BioPharma platform features the following functionality:
    A Vast Drug Database – Robust forecast data with 200+ brokers, and over a dozen third-party data sources.

VISIBLE ALPHA LAUNCHES NEW BIOPHARMA PLATFORM

Retrieved on: 
Tuesday, February 6, 2024
Growth, Research, Clinical trial, News, Metadata, FDA, MOA, Alpha, Data and information visualization, Pharmaceutical industry

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Visible Alpha, a financial technology company that enhances the investment research process by extracting value from sell-side analyst models, research reports and corporate access events, today announced the launch of its newest data and granular financial information platform Visible Alpha BioPharma.  

Key Points: 
  • NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Visible Alpha, a financial technology company that enhances the investment research process by extracting value from sell-side analyst models, research reports and corporate access events, today announced the launch of its newest data and granular financial information platform Visible Alpha BioPharma.
  • With the launch of Visible Alpha BioPharma, Visible Alpha is providing investment professionals and drug developers with a one-stop-shop for comprehensive drug data and granular financial information to swiftly identify new opportunities, evaluate market competitiveness, gauge market expectations, analyze historical data, access forward-looking estimates and conduct rapid analysis at the drug level.
  • Visible Alpha's new BioPharma platform will allow investment, equity research, and drug development professionals to:
    Gain insights into market trends, investor sentiment and the changing projections surrounding drug performance with detailed financial data.
  • The new Visible Alpha BioPharma platform features the following functionality:
    A Vast Drug Database – Robust forecast data with 200+ brokers, and over a dozen third-party data sources.

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

Retrieved on: 
Tuesday, January 30, 2024
Traffic barrier, Survival, NCI, Fast Track, Patient, Safety, Central nervous system, Glomus tumor, MOA, CNS, Bone marrow, Hope, SBIR, Ependymoma, Cancer, Pharmaceutical industry

“Treatment of pediatric patients with relapsed and refractory high-grade glioma and ependymoma is extremely challenging.

Key Points: 
  • “Treatment of pediatric patients with relapsed and refractory high-grade glioma and ependymoma is extremely challenging.
  • There are limited treatment options and high unmet clinical need for patients suffering from this aggressive cancer,” said Dr. Sameer Farouk Sait, pediatric hematologist-oncologist and assistant attending at Memorial Sloan Kettering Cancer Center.
  • “We understand the profound impact pediatric high-grade gliomas have on the lives of young patients and their families,” commented James Caruso, president and CEO of Cellectar.
  • We are hopeful its novel MOA will provide a meaningful treatment option for these young patients.”